Clinical Trial Update: Dose-Response Study of Ibalizumab (Monoclonal Antibody) Plus Optimized Background Regimen in Patients With HIV-1 [Phase 2]

View source ↗

Summary

This update reports results from a Phase 2 dose‑response study of ibalizumab added to an optimized background regimen in HIV-1 patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Ibalizumab (ibalizumab)

Snippet

Sponsor: TaiMed Biologics Inc. | Conditions: HIV | Phase 2 | Status: COMPLETED | Results posted: 2014-04-17